

# Echocardiographic Imaging Challenges in Obesity: Guideline Recommendations and Limitations of Adjusting to Body Size

Maninder Singh, MBBS; Anuradha Sethi, MPH; Abhishek K. Mishra, MBBS; Navin K. Subrayappa, MBBS; Dwight D. Stapleton, MD; Patricia A. Pellikka, MD

According to statistics by the World Health Organization<sup>1</sup> and the Centers for Disease Control,<sup>2</sup>  $\approx 20\%$  of adults in Europe and  $\approx 40\%$  in the United States are obese. In some series nearly half of patients undergoing outpatient echocardiography were noted to have a body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup>.<sup>3</sup> Obese patients present unique challenges for optimal echocardiographic imaging and interpretation.<sup>3</sup> One such challenge is optimal adjustment for body size in these patients. Guidelines for cardiac imaging frequently recommend adjusting for the body size of the patient for assessment of left atrial (LA) size, left ventricular (LV) mass, and valvular hemodynamics. Several parameters such as height with various allometric powers or body surface area (BSA) have been studied. However, most guidelines recommend indexing to BSA. In this article, we have summarized the guideline recommendations regarding adjustment for body size in the obese, evidence base, potential pitfalls, and clinical implications related to using weight-dependent indexing methods in obese (BMI  $>30$  kg/m<sup>2</sup>) and morbidly obese (BMI  $>40$  kg/m<sup>2</sup>) individuals (Figure 1A and 1B). Guidelines for various recommendations are summarized in Table.<sup>4-16</sup>

## LA Size

Assessment of LA size is prognostically important and is also an integral part of various echocardiographic diagnostic

algorithms such as assessment of diastolic function, quantification of mitral valve disease, and assessment of the likelihood of atrial arrhythmias.

## Quantification of LA Size: Guideline Recommendations

Society guidelines (American Society of Echocardiography/European Association of Cardiovascular Imaging [ASE/EACVI] chamber quantification guidelines, ASE/EACVI guidelines on assessment of LV diastolic function, and ASE/EACVI guidelines on echocardiography in hypertension) recommend using BSA to index LA volume to assess LA size,<sup>4-6</sup> regardless of the BMI or BSA of the patient. Indexed LA volume is intended to neutralize the effect of sex on LA size. These documents provide no specific recommendations for obese individuals; the threshold of 34 mL/m<sup>2</sup> to define normal is used in all. Only the ASE/EACVI guidelines on echocardiography in hypertension acknowledge that indexing LA volume to BSA corrects for obesity-related LA dilatation, and as a result, obesity-related LA dilatation may remain undetected.<sup>6</sup> On the other hand, the European Society of Cardiology (ESC) guidelines on management of arterial hypertension in adults recommend using LA volume indexed to height<sup>2</sup> to define normal LA size ( $\leq 18.5$  mL/m<sup>2</sup> for men;  $\leq 16.5$  mL/m<sup>2</sup> for women).<sup>7</sup>

## Reference LA Indexed Volume: Evidence


Established reference range for LA size is based either on population studies that included normal individuals or studies that have evaluated outcomes based on LA size. The mean BSA in population studies that evaluated LA size in healthy individuals and form the basis of recommendations by the ASE/EACVI chamber quantification guidelines, ranged from 1.44 to 1.84 m<sup>2</sup>.<sup>17-19</sup> A study that showed LA volume indexed to BSA to be superior compared with linear diameter (anteroposterior diameter in parasternal view) for prediction of first atrial fibrillation, congestive heart failure, stroke, transient ischemic attack, or other cardiovascular outcomes included patients with a mean BMI around 28 kg/m<sup>2</sup>.<sup>20</sup> To

From the Department of Cardiology, Guthrie Medical Group/Robert Packer Hospital, Sayre, PA (M.S., A.K.M., N.K.S.); Geisinger Commonwealth School of Medicine, Scranton, PA (M.S.); Department of Strategic Planning and Marketing, Guthrie Medical Group, Sayre, PA (A.S.); OSF Healthcare, Peoria, IL (D.D.S.); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (P.A.P.).

**Correspondence to:** Maninder Singh, MBBS, FACC, Guthrie Medical Group/Robert Packer Hospital, 1 Guthrie Square, Sayre, PA 18840. E-mail: maninder.amc@gmail.com

*J Am Heart Assoc.* 2020;9:e014609. DOI: 10.1161/JAHA.119.014609.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.



**Figure 1.** Imaging pitfalls in obese individuals. **A**, Illustration showing discrepancies in assessment of LA volume, diastolic function, and LVH assessment in a lean vs obese patient of similar height. BMI indicates body mass index; BSA, body surface area (Mosteller formula); i, indexed; IVDd, internal left ventricular diameter in diastole; IVS, interventricular septum; LA, left atrial; LV, left ventricle; LVH, left ventricular hypertrophy; PW, posterior wall; TRV, tricuspid regurgitant velocity. **B**, Illustration showing discrepancies in assessment of aortic stenosis, flow state, and assessment of PPM in a lean vs an obese patient of similar height. AVA indicates aortic valve area; BMI, body mass index; BSA, body surface Area; EOA, effective orifice area; i, indexed; MG, mean gradient; PPM, patient prosthesis mismatch; PV, peak velocity; SV, Stroke Volume. In echocardiograms: e' indicates Mitral Annular Tissue Doppler Velocity; E/A, Ratio of E wave and A wave; E/e', Ratio of E wave to mitral annular velocity; LVOT, LV outflow tract; VTI, Velocity Time Integral.

the best of our knowledge, no studies have assessed outcomes based on various indexing methods for LA size assessment exclusively in patients with BMI  $\geq 30$  kg/m<sup>2</sup>.

Obesity is known to be associated with LA structural and functional remodeling<sup>21</sup> and a higher prevalence of conditions

that are mediated by LA enlargement such as diastolic heart failure and atrial fibrillation. When LA size was indexed based on methods that were not weight dependent, a higher prevalence of LA enlargement was noted in obese patients.<sup>22,23</sup> Stritzke and colleagues<sup>23</sup> studied 1212 individuals who had an ECG at

baseline and 10 years later. They assessed LA size indexed to height and found that obesity was the strongest risk factor beside aging for LA enlargement. The prevalence of LA enlargement was significantly lower when LA enlargement was assessed using the traditional method of indexing LA size to BSA, especially in obese individuals. Another study showed that obesity was the strongest predictor of LA enlargement (measured as a linear diameter in parasternal view) in hypertensive patients.<sup>22</sup>

## Clinical Implications

Besides hypertension and age, obesity is the main determinant for LA enlargement<sup>6</sup> and represents a pathological process, not just a physiological increase. Using weight-dependent methods such as BSA to index LA volume in obese and morbidly obese patients may underestimate the magnitude of LA dilatation and underestimate the effect of obesity on LA remodeling. Clinically, this may translate into underestimation of diastolic dysfunction, prediction of future cardiovascular events, and prevalence of LA enlargement in obese patients.

Clinicians can consider using BSA to estimate LA size in obese individuals. If LA is dilated based on this method, it is reasonable to quantify LV diastolic dysfunction based on this. However, the report should mention that the LA size may be underestimated. If LA size is normal when indexed to BSA in obese individuals, we recommend using height-based indexing as recommended by the ESC hypertension guidelines.<sup>7</sup> Alternatively, clinicians should consider using recommendations from ESC/ASE 2005 guidelines,<sup>24</sup> which provided lower thresholds for defining LA dilatation (normal  $\leq 28 \text{ mL/m}^2$ ) (Figure 2).

## LV Mass

Assessment of LV mass by echocardiography or other imaging modalities is clinically and epidemiologically important. Clinically, LV hypertrophy (LVH) is associated with adverse clinical events in patients. Epidemiologically, prevalence of LVH and risk of associated adverse cardiovascular events are important public health measures and are useful to identify the burden of hypertension.

## Adjusting LV Mass to Body Size: Guideline Recommendations

ASE/EACVI 2015 chamber quantification guidelines<sup>4</sup> acknowledge that height-based indexing has advantages over BSA-based indexing in obese individuals but still recommend reporting LV mass values indexed to the BSA to define LV hypertrophy in all patients, as most of the population studies


reported LV mass indexed to BSA. These guidelines also do not provide height-specific cutoffs for defining LVH. Another ASE/EACVI guideline published in 2015 regarding use of echocardiography in hypertension<sup>6</sup> provides height-specific cutoffs for quantification of LVH. Although this document also suggests that height-based indexing preserves the effect of obesity on LV mass, it does not provide specific recommendations on the best method for indexing in obese patients. On the other hand, the ESC guidelines on management of arterial hypertension recommend height-based indexing to define LVH ( $\text{LV mass/height in m}^{2.7}$ ), whereas indexing LV mass to BSA is only recommended for patients with normal weight.<sup>7</sup>

## Pathological LVH and Cardiac Risk

The ideal method to adjust to body size for LV mass remains controversial in obese subjects, but studies have tended to favor height-based indexing. Some studies have shown that LV mass indexed to BSA best identifies clinical events as compared with other methods,<sup>25</sup> whereas other studies have favored height-based indexing, especially in overweight and obese subjects.<sup>26,27</sup> Another study showed that height-based indexing predicted mortality and cardiovascular outcomes better than BSA-based indexing in dialysis patients.<sup>28</sup>

Outcome studies comparing the best indexing method in obese patients are limited. Also, no population studies have exclusively studied echocardiographic characteristics in “otherwise healthy” obese individuals. Most observational studies in obese and morbidly obese patients have reported LVH using LV mass indexed to height, with various allometric powers (most commonly 2.7).<sup>29</sup> Studies in patients undergoing bariatric surgery have shown a significant regression in LV mass and LVH after weight loss. One study that indexed LV mass to BSA in morbidly obese subjects did not show any significant change in LVH after weight loss, even though there was a significant decrease in LV mass after bariatric surgery.<sup>30</sup> These studies suggest that indexing LV mass to BSA tends to attenuate the effect of obesity on LVH.

Even fewer studies have assessed the effect of indexing methods on yet another important epidemiological parameter, the population-attributable risk percentage (PAR%). The PAR% is important from a population health standpoint as it better defines the proportion of disease in the population that can be attributed to a particular risk factor. Two studies in 2005 compared PAR% associated with LVH with various indexing methods. In 1 cohort with a low prevalence of obesity (22%),<sup>31</sup> the PAR% attributable to LVH was similar for various indexing methods (BSA, height, height<sup>2.13</sup>, height<sup>2.7</sup>), even though prevalence of LVH was higher when LV mass was adjusted by height-based indexing methods in comparison to BSA. The other study included a cohort of patients with a high prevalence of obesity (56%)<sup>32</sup> and showed that height-based



**Figure 2.** Proposed indexing methods for chamber quantification in obese individuals. A schematic showing proposed alternative indexing methods for obese individuals to avoid misclassification. 2D indicates 2-dimensional; abn, abnormal; AVA, aortic valve area; BMI, body mass index; BSA, body surface area; LVOT, left ventricular outflow tract; SVi, Stroke Volume (indexed); SV, stroke volume.

indexing was superior to BSA in assessing PAR% attributable to LVH and prevalence of LVH in this population.

### Physiological LVH

Certain physiological conditions such as pregnancy and endurance training can lead to morphological LVH, which in these cases, is benign and reversible. In athletes, LVH has commonly been described in terms of absolute wall thickness, rather than indexed values.

### Clinical and Public Health Implications

LVH in obese patients is a pathological process (Figure 3) and has been shown to be associated with important clinical events.<sup>29</sup> Using BSA-based indexing may result in underestimation of the prevalence of LVH in obese patients. Moreover,


in a population with high prevalence of obesity, LV mass indexed to height is a better method compared with BSA-based indexing from an epidemiological standpoint to assess prevalence of LVH and PAR%.

We recommend indexing LV mass to height<sup>2,7</sup> in obese individuals as recommended by the ESC hypertension guidelines<sup>7</sup> (Figure 2). BSA should not be used to index LV mass when  $\text{BMI} \geq 30 \text{ kg/m}^2$ .

### Assessment of Stroke Volume

Stroke volume indexed to body surface area is particularly important in patients suspected to have heart failure or deemed to have severe aortic stenosis by the continuity method, but with low transaortic gradients (mean gradient  $< 40 \text{ mm Hg}$  and peak velocity  $< 4 \text{ m/s}$ ). Major society guidelines recommend assessment of indexed stroke volume





**Figure 3.** Myocardial adaptations in obesity. Illustration showing some of the physiological and pathological myocardial adaptations relevant to indexing in obese individuals. LA indicates left atrium; LV, left ventricle; ↑, increase.

in these situations to define the flow state as a possible explanation for low gradients, or low-flow, low-gradient aortic stenosis.

### Supporting Evidence

Multiple studies have shown worse cardiovascular outcomes in patients with low-flow, low-gradient aortic stenosis and paradoxical low-flow, low-gradient aortic stenosis based on a stroke volume index cutoff of 35 mL/m<sup>2</sup>. However, obese patients were underrepresented in most of these studies.<sup>33–35</sup> Limited echocardiographic data regarding stroke volume in obese patients come from studies that evaluated patients undergoing bariatric surgery. However, stroke volume index was not consistently reported in these studies.<sup>36,37</sup> Studies using modalities such as cardiac catheterization in morbidly obese patients have reported higher stroke volume.<sup>30,38</sup> A study based on cardiac catheterization data suggested that indexing stroke volume to BSA can eliminate the effects of increased body size on stroke volume, and a uniform cutoff can be used for a wide range of BMI and BSA.<sup>39</sup>

### Clinical Implications

Cardiac output and stroke volume increase with increased body weight and BMI, which represent a physiological adaptation to increased circulating blood volume and metabolic needs (Figure 3). Unlike other pathological changes in cardiac structure, increased stroke volume in obese patients does not seem to correlate independently with adverse cardiac outcomes, and hence, using a single cutoff to define a normal flow state across a wide range of body size and BMI is feasible.

Clinicians can consider using stroke volume indexed to BSA to define the flow state in obese individuals. However,

if a low-flow state is present, we recommend confirming cardiac output by other methods, especially in the setting of technically limited studies (suboptimal 2D imaging or Doppler alignment), which are not uncommon in obese individuals (Figure 2).

### Quantification of Aortic Stenosis Severity

In addition to several Doppler-based and nonindexed parameters, the American College of Cardiology/American Heart Association (ACC/AHA) valve guidelines<sup>8</sup> and the appropriate use criteria for treatment of severe aortic stenosis<sup>9</sup> also suggest a cutoff of  $\leq 0.6$  cm<sup>2</sup>/m<sup>2</sup> to define severe aortic stenosis. However, the ACC/AHA guidelines or the appropriate use criteria do not clarify whether this approach of using indexed aortic valve area (AVA) in making treatment decisions is applicable to patients with obesity. On the other hand, the ASE/EACVI guidelines<sup>10</sup> recommend using indexed valve area to quantify aortic stenosis primarily in patients with small body size. ASE/EACVI guidelines recognize that the role of indexing is controversial, particularly in obese patients. The ESC guideline recommendations have changed over time. The previous version of ESC 2007 guidelines<sup>11</sup> recommended indexing AVA in patients with “unusually small” or “unusually large” body size. This was subsequently changed to include only “unusually small” body size in the ESC 2012 version.<sup>12</sup> The latest version of the ESC guidelines published in 2017, does not provide any recommendations for quantifying aortic stenosis based on indexed AVA.<sup>13</sup>

### Evidence Base

Autopsy studies have shown that AVA in infants and children is directly related to age, weight, and the BSA.<sup>40</sup> However, this is not true in adults. In an autopsy study by Westaby

**Table.** Comparison of Various Guideline Recommendations for Indexing Left Atrial Size, Left Ventricular Mass, Aortic Stenosis, and Patient-Prosthesis Mismatch

Left Atrial Size					
	ASE/EACVI-2015 Chamber Quantification Guidelines <sup>4</sup>	ASE/EACVI-2016 Left Ventricular Diastolic Function Guidelines <sup>5</sup>	ASE/EACVI-2015 Echocardiography in Hypertension <sup>6</sup>	ESC-2018 Guidelines on Hypertension Management <sup>7</sup>	ACC/AHA
LA volume (indexed to BSA)	Normal ≤34 mL/m <sup>2</sup>	Normal ≤34/m <sup>2</sup>	Normal ≤34/m <sup>2</sup> (obesity-related LA enlargement may remain undetected)	None	None
LA volume (indexed to height <sup>2</sup> )	None	None	None	≤18.5 mL/m <sup>2</sup> (men) ≤16.5 mL/m <sup>2</sup> (women)	None
Left Ventricular Hypertrophy					
	ASE/EACVI-2015 Chamber Quantification Guidelines <sup>4</sup>	ASE/EACVI-2015 Echocardiography in Hypertension <sup>6</sup>	ESC-2018 Guidelines on Hypertension Management <sup>7</sup>	ACC/AHA	
LV mass by linear method (indexed to BSA)	≤95 g/m <sup>2</sup> (women) ≤115 g/m <sup>2</sup> (men)	≤95 g/m <sup>2</sup> (women) ≤115 g/m <sup>2</sup> (men) (obesity-related LVH may remain undetected)	≤95 g/m <sup>2</sup> (women) ≤115 g/m <sup>2</sup> (men) May be used in normal-weight patients	None	
LV mass by linear method (indexed to height)	None	≤44 g/m <sup>2.7</sup> (women) ≤48 g/m <sup>2.7</sup> (men) ≤99 g/m (women) ≤126 g/m (men)	≤47 g/m <sup>2.7</sup> (women) ≤50 g/m <sup>2.7</sup> (men) (height in m <sup>2.7</sup> )	None	
Classification of Aortic Stenosis Based on Indexed Values					
	ACC/AHA 2014/2017 Valve Guidelines <sup>8</sup> /AUC-2017 for Treatment of Aortic Stenosis <sup>9</sup>	ASE/EACVI-2017 Guidelines on Assessment of Aortic Stenosis <sup>10</sup>	ESC-2007 Valve Guidelines <sup>11</sup>	ESC-2012 Valve Guidelines <sup>12</sup>	ESC-2017 Valve Guidelines <sup>13</sup>
Severe aortic stenosis based on BSA	≤0.6 cm <sup>2</sup> /m <sup>2</sup>	<0.6 cm <sup>2</sup> /m <sup>2</sup> controversial in obese, important for children, adolescents and small adults	<0.6 cm <sup>2</sup> /m <sup>2</sup> for unusually small or unusually large individuals	<0.6 cm <sup>2</sup> /m <sup>2</sup> for unusually small individuals	No recommendations provided
Patient-Prosthesis Mismatch					
	ACC/AHA 2014/2017 Valve Guidelines <sup>8</sup>	ASE-2009 Guidelines on Echo Evaluation of Prosthetic Valve <sup>14</sup>	EACVI-2016 Guidelines for Imaging of Prosthetic Valves <sup>15</sup>	VARC-2-2012 Consensus Document <sup>16</sup>	ESC
PPM	≤0.85 cm <sup>2</sup> /m <sup>2</sup>	≤0.85 cm <sup>2</sup> /m <sup>2</sup>	≤0.85 cm <sup>2</sup> /m* ≤0.70 cm <sup>2</sup> /m†	≤0.85 cm <sup>2</sup> /m <sup>2</sup> * ≤0.70 cm <sup>2</sup> /m <sup>2</sup> †	None
Severe PPM	<0.65 cm <sup>2</sup> /m <sup>2</sup>	<0.65 cm <sup>2</sup> /m <sup>2</sup>	<0.65 cm <sup>2</sup> /m* <0.55 cm <sup>2</sup> /m†	<0.65 cm <sup>2</sup> /m <sup>2</sup> * <0.60 cm <sup>2</sup> /m <sup>2</sup> †	None

ACC/AHA indicates American College of Cardiology/American Heart Association; ASE, American Society of Echocardiography; AUC, appropriate use criteria; BMI, body mass index; BSA, body surface area; EACVI, European Association of Cardiovascular Imaging; ESC, European Society of Cardiology; LA, left atrium; LV, left ventricle; LVH, left ventricular hypertrophy; PPM, patient-prosthesis mismatch; VARC, Valve Academic Research Consortium.

\*BMI  $<30$  kg/m<sup>2</sup>.

†BMI  $\geq 30$  kg/m<sup>2</sup>.

et al, the correlation between AVA and BSA in adults (16-83 years) was poor.<sup>41</sup>

Multiple studies have shown that indexing AVA by BSA overclassifies aortic stenosis as severe without improving predictive accuracy for adverse events in comparison to nonindexed valve area.<sup>42-45</sup> This is especially true in obese individuals.<sup>44,45</sup> Some studies<sup>43</sup> have suggested a height-based indexed cutoff of  $<0.45$  cm<sup>2</sup>/m or a lower cutoff of  $<0.4$  cm<sup>2</sup>/m<sup>2</sup> to be better predictive of adverse events at 2 years in contrast to the recommended cutoff of  $<0.6$  cm<sup>2</sup>/m<sup>2</sup>.

## Clinical Implications

Based on the above evidence, it can be concluded that classification of aortic stenosis based on BSA is arbitrary in the absence of any definite physiological correlation between the BSA and the normal aortic valve area in adults. This is especially true in obese patients, where excess weight accounts for an increase in BSA. Using a cutoff of  $<0.6$  cm<sup>2</sup>/m<sup>2</sup> to define severe aortic stenosis may inadvertently overestimate the true severity and prevalence of aortic stenosis in obese patients, and it does not provide any

additive prognostic information in these patients. Based on this, we do not recommend indexing AVA in obese patients to make treatment decisions. Indexing AVA should be reserved in patients with smaller body size.<sup>10</sup>

## Patient-Prosthesis Mismatch

Presence of a patient-prosthesis mismatch (PPM) is an important adverse prognostic indicator in patients with prosthetic valves and is defined by effective orifice area (usually derived by echocardiography) indexed to BSA. Some guideline documents provide different thresholds to define PPM in obese and lean patients, whereas other documents provide uniform threshold regardless of body size. The ACC/AHA<sup>8</sup> and the ASE guidelines<sup>14</sup> provide a uniform threshold of indexed effective orifice area  $<0.85$  and  $<0.65$   $\text{cm}^2/\text{m}^2$  to define PPM and severe PPM, respectively, regardless of the BSA or BMI. The EACVI<sup>15</sup> and the Valve Academic Research Consortium-2<sup>16</sup> guidelines recommend different thresholds for obese patients to define PPM (severe PPM defined as  $<0.55$   $\text{cm}^2/\text{m}^2$  and  $<0.60$   $\text{cm}^2/\text{m}^2$  respectively). Similarly, some documents have recommended different thresholds to define normal prosthetic effective orifice area in patients with BSA  $>1.6$   $\text{m}^2$ .<sup>16</sup> These recommendations are summarized in Table.

## Evidence Base

Older studies that showed that patients with PPM have adverse prognosis mostly included individuals with average BMI and BSA, ranging from  $1.56 \pm 0.12$  to  $1.84 \pm 0.20$   $\text{m}^2$ .<sup>46,47</sup> Studies that included obese individuals have shown conflicting findings. In a study by Mohty and colleagues<sup>48</sup> PPM was noted to be associated with a higher mortality only in patients with a BMI  $<30$   $\text{kg}/\text{m}^2$ . In obese patients PPM was not a predictor of higher mortality. Similar findings were reported by another study<sup>49</sup> in which PPM was a predictor of adverse events in lean and overweight patients but not in obese patients. In a meta-analysis of 58 studies a BMI  $>28$   $\text{kg}/\text{m}^2$  had a weaker impact on mortality (hazard ratio 1.14; 95% CI 1.07-1.22,  $P=0.0001$ ) compared with BMI  $<28$   $\text{kg}/\text{m}^2$  (hazard ratio 2.37; 95% CI 1.42-3.95;  $P=0.003$ ).<sup>50</sup>

The above findings contrast with some recent studies from national database registries. Two studies from the Society of Thoracic Surgeons/Transcatheter Valve Therapy,<sup>51</sup> and the Society of Thoracic Surgeons adult cardiac surgery database<sup>52</sup> registries showed that PPM (effective orifice area  $<0.65$   $\text{cm}^2/\text{m}^2$ ) was also associated with poor outcomes in patients with BMI  $\geq 30$   $\text{kg}/\text{m}^2$ . However, these studies did not assess the effect of worsening severity of obesity (class 2 or greater) on clinical outcomes or whether the association of PPM with worse outcomes is applicable across all BMI ranges. It would be helpful to know if there is an upper limit of BMI beyond which

there is no association of poor outcomes with PPM, and a lower threshold as suggested by Valve Academic Research Consortium-2 and EACVI guidelines may be more appropriate.

## Clinical Implications

Using the thresholds as recommended by the ACC/AHA guidelines to define PPM may overestimate the severity and prevalence of PPM in obese patients. However, evidence for use of these thresholds to assess long-term outcomes is conflicting.

It is probably reasonable to use lower thresholds to define PPM (Figure 2) (especially in patients with class 2 and class 3 obesity) as recommended by the Valve Academic Research Consortium-2 and EACVI guidelines. This is particularly important when a valve intervention is considered due to PPM. However, more studies with head-to-head comparison of differing thresholds recommended by various guidelines are needed to better define the optimal cutoff in obese patients.

## Conclusions

Optimal adjustment of echocardiographic parameters for body size in obese individuals remains a challenge. In obese individuals excess weight contributes to an increased BSA and using weight-based indexing methods (BSA) for chamber quantification, LV diastolic function assessment and quantification of valvular hemodynamics may result in misclassification and misleading conclusions. We also found multiple disagreements among various guideline recommendations regarding adjustment for body size in obese individuals. Although a uniform threshold can be used to define parameters that are physiological in obesity such as stroke volume index, indexing to BSA for other morphological changes in the cardiac structures that represent a pathological change such as LA dilatation or LVH should be avoided. Similarly, classifying aortic stenosis based on BSA and defining PPM in obese patients should be used with caution. Further research is needed to better define the best way to adjust for body size in obese individuals.

## Sources of Funding

This work was supported by the Donald Guthrie Research Foundation, Sayre, PA.

## Disclosures

Singh received reimbursement from C3 Interventional Academy for attending C3 conference at Orlando, FL (June 2019) and minor reimbursement for attending a workshop: Abiomed and Siemens. Subrayappa received reimbursement for attending a workshop: Abiomed and Siemens. The remaining authors have no disclosures to report.

## References

1. Data and Statistics. Available at: <http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics>. Accessed September 21, 2019.
2. FastStats—Overweight Prevalence. Available at: <https://www.cdc.gov/nchs/fastats/obesity-overweight.htm>. Accessed September 21, 2019.
3. Finkelhor RS, Moallem M, Bahler RC. Characteristics and impact of obesity on the outpatient echocardiography laboratory. *Am J Cardiol*. 2006;97:1082–1084.
4. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt J-U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1–39.
5. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29:277–314.
6. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, Ghottdiener J, Haluska B, Offili E, Segers P, Senior R, Tapp RJ, Zamorano JL. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). *J Am Soc Echocardiogr*. 2015;28:727–754.
7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, De Backer G, Heagerty AM, Agewall S, Bochud M, Borghi C, Boutouyrie P, Brguljan J, Bueno H, Caiani EG, Carlberg B, Chapman N, Cifková R, Cleland JGF, Collet J-P, Coman IM, de Leeuw PW, Delgado V, Dendale P, Diener H-C, Dorobantu M, Fagard R, Farsang C, Ferrini M, Graham IM, Grassi G, Haller H, Hobbs FDR, Jelakovic B, Jennings C, Katus HA, Kroon AA, Leclercq C, Lovic D, Lurbe E, Manolis AJ, McDonagh TA, Messerli F, Muiesan ML, Nixdorff U, Olsen MH, Parati G, Perk J, Piepoli MF, Polonia J, Ponikowski P, Richter DJ, Rimoldi SF, Roffi M, Sattar N, Seferovic PM, Simpson IA, Sousa-Uva M, Stanton AV, van de Borne P, Vardas P, Volpe M, Wassmann S, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J-P, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Zamorano JL, Tsioufis C, Lurbe E, Kreutz R, Bochud M, Rosei EA, Jelakovic B, Azizi M, Januszewicz A, Kahan T, Polonia J, van de Borne P, Williams B, Borghi C, Polonia J, Parati G, Clement DL, Coca A, Manolis A, Lovic D, Benkhedda S, Zelveian P, Siostrzonek P, Najafav R, Pavlova O, De Pauw M, Dizdarevic-Hudic L, Raev D, Karpettas N, Linhart A, Olsen MH, Shaker AF, Viigimaa M, Metsärinne K, Vavilakis M, Halimi J-M, Pagava Z, Schunkert H, Thomopoulos C, Páll D, Andersen K, Shechter M, Mercuro G, Bajraktari G, Romanova T, Truškinskis K, Saade GA, Sakalyte G, Noppe S, DeMarco DC, Caraus A, Wittekoek J, Aklonis TA, Jankowski P, Polonia J, Vinereanu D, Baranovs EI, Foscoli M, Dikic AD, Filipova S, Fras Z, Bertomeu-Martínez V, Carlberg B, Burkard T, Sdiri W, Aydogdu S, Sirenko Y, Brady A, Weber T, Lazareva I, De Backer T, Sokolovic S, Jelakovic B, Widimsky J, Viigimaa M, Pörsti I, Denolle T, Krämer BK, Stergiou GS, Parati G, Truškinskis K, Miglinas M, Gerdtts E, Tykarski A, de Carvalho Rodrigues M, Dorobantu M, Chazova I, Lovic D, Filipova S, Brguljan J, Segura J, Gottsäter A, Pechère-Bertschi A, Erdine S, Sirenko Y, Brady A. 2018 ESC/ESH guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021–3104.
8. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM, Thomas JD, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Creager MA, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Stevenson WG, Yancy CW. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129:2440–2492.
9. Bonow RO, Brown AS, Gillam LD, Kapadia SR, Kavinsky CJ, Lindman BR, Mack MJ, Thourani VH. ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 appropriate use criteria for the treatment of patients with severe aortic stenosis. *J Am Coll Cardiol*. 2017;70:2566–2598.
10. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, Lancellotti P, LeFebvre M, Miller F, Otto CM. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2017;30:372–392.
11. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A, Priori SG, Blanc J-J, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Zamorano JL, Angelini A, Antunes M, Fernandez MAG, Gohlke-Baerwolf C, Habib G, McMurray J, Otto C, Pierard L, Pomar JL, Prendergast B, Rosenhek R, Uva MS, Tamargo J. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. *Eur Heart J*. 2006;28:230–268.
12. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schäfers H-J, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Ž, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Popescu BA, Von Segesser L, Badano LP, Bunc M, Claeys MJ, Drinkovic N, Filippatos G, Habib G, Kappetein AP, Kassab R, Lip GYH, Moat N, Nickenig G, Otto CM, Pepper J, Piazza N, Pieper PG, Rosenhek R, Shuka N, Schwammenthal E, Schwitler J, Mas PT, Trindade PT, Walther T. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J*. 2012;33:2451–2496.
13. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38:2739–2791.
14. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, Khandheria BK, Levine RA, Marx GR, Miller FA, Nakatani S, Quinones MA, Rakowski H, Rodriguez LL, Swaminathan M, Waggoner AD, Weissman NJ, Zabalgoitia M; American Society of Echocardiography's Guidelines and Standards Committee, Task Force on Prosthetic Valves, American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, European Association of Echocardiography, European Society of Cardiology, Japanese Society of Echocardiography, Canadian Society of Echocardiography, American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound. *J Am Soc Echocardiogr*. 2009;22:975–1014.
15. Lancellotti P, Pibarot P, Chambers J, Edvardsen T, Delgado V, Dulgheru R, Pepi M, Cosyns B, Dweck MR, Garbi M, Magne J, Nieman K, Rosenhek R, Bernard A, Lowenstein J, Vieira MLC, Rabschowsky A, Vyhmeister RH, Zhou X, Zhang Y, Zamorano J-L, Habib G. Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2016;17:589–590.
16. Kappetein AP, Head SJ, Gèneux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es G-A, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Eur Heart J*. 2012;33:2403–2418.
17. Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C, Kacharava G, Athanassopoulos GD, Barone D, Baroni M, Cardim N, Gomez De Diego JJ, Hagendorff A, Henri C, Hristova K, Lopez T, Magne J, De La Morena G, Popescu BA, Penicka M, Ozyigit T, Rodrigo Carbonero JD, Salustri A, Van De Veire N, Von Bardeleben RS, Vinereanu D, Voigt J-U, Zamorano JL, Donal E, Lang RM, Badano LP, Lancellotti P. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. *Eur Heart J Cardiovasc Imaging*. 2014;15:680–690.
18. Nistri S, Galderisi M, Ballo P, Olivetto I, D'Andrea A, Pagliani L, Santoro A, Papasso B, Innelli P, Cecchi F, Mondillo S. Determinants of echocardiographic left atrial volume: implications for normalcy. *Eur J Echocardiogr*. 2011;12:826–833.
19. Whitlock M, Garg A, Gelow J, Jacobson T, Broberg C. Comparison of left and right atrial volume by echocardiography versus cardiac magnetic resonance imaging using the area-length method. *Am J Cardiol*. 2010;106:1345–1350.
20. Tsang TSM, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR, Cha SS, Seward JB. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? *J Am Coll Cardiol*. 2006;47:1018–1023.
21. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, Mahajan R, Kuklik P, Zhang Y, Brooks AG, Nelson AJ, Worthley SG, Abhayaratna WP, Kalman JM, Wittert GA, Sanders P. Obesity results in progressive atrial



- structural and electrical remodeling: implications for atrial fibrillation. *Heart Rhythm*. 2013;10:90–100.
22. Gottdiener JS, Reda DJ, Williams DW, Materson BJ. Left atrial size in hypertensive men: influence of obesity, race and age. *J Am Coll Cardiol*. 1997;29:651–658.
  23. Stritzke J, Markus MRP, Duderstadt S, Lieb W, Luchner A, Döring A, Keil U, Hense H-W, Schunkert H; MONICA/KORA Investigators. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging—the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. *J Am Coll Cardiol*. 2009;54:1982–1989.
  24. Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P, Picard M, Roman M, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W. Recommendations for chamber quantification. *Eur J Echocardiogr*. 2006;7:79–108.
  25. Ferrara LA, Vaccaro O, Cardoni O, Laurenzi M, Mancini M, Zanchetti A. Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. *Am J Hypertens*. 2005;18:1282–1287.
  26. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, Claessens T, Gillebert TC, St John-Sutton M, Rietzschel ER. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. *Hypertension*. 2010;56:91–98.
  27. Cuspidi C, Meani S, Negri F, Giudici V, Valerio C, Sala C, Zanchetti A, Mancia G. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives? *J Hum Hypertens*. 2009;23:728–734.
  28. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS; CREED Investigators. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. *J Am Soc Nephrol*. 2001;12:2768–2774.
  29. Cuspidi C, Rescaldani M, Sala C, Grassi G. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. *J Hypertens*. 2014;32:16–25.
  30. Rider OJ, Francis JM, Ali MK, Petersen SE, Robinson M, Robson MD, Byrne JP, Clarke K, Neubauer S. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. *J Am Coll Cardiol*. 2009;54:718–726.
  31. de Simone G, Devereux R, Maggioni A, Gorini M, DeDivitiis O, Verdecchia P; MAVI (MASSA Ventricolare sinistra nell'ipertensione) Study Group. Different normalizations for body size and population attributable risk of left ventricular hypertrophy: the MAVI study. *Am J Hypertens*. 2005;18:1288–1293.
  32. de Simone G, Kizer J, Chinali M, Roman M, Bella J, Best L, Lee E, Devereux R; Strong Heart Study Investigators. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. *Am J Hypertens*. 2005;18:191–196.
  33. Clavel M-A, Dumesnil JG, Capoulade R, Mathieu P, Sénéchal M, Pibarot P. Outcome of patients with aortic stenosis, small valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction. *J Am Coll Cardiol*. 2012;60:1259–1267.
  34. Herrmann HC, Pibarot P, Hueter I, Gertz ZM, Stewart WJ, Kapadia S, Tuzcu EM, Babaliaros V, Thourani V, Szeto WY, Bavaria JE, Kodali S, Hahn RT, Williams M, Miller DC, Douglas PS, Leon MB. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis. *Circulation*. 2013;127:2316–2326.
  35. Le Ven F, Freeman M, Webb J, Clavel M-A, Wheeler M, Dumont É, Thompson C, De Laroche R, Moss R, Doyle D, Ribeiro HB, Urena M, Nombela-Franco L, Rodés-Cabau J, Pibarot P. Impact of low flow on the outcome of high-risk patients undergoing transcatheter aortic valve replacement. *J Am Coll Cardiol*. 2013;62:782–788.
  36. Kaier TE, Morgan D, Grapsa J, Demir OM, Paschou SA, Sundar S, Hakky S, Purkayastha S, Connolly S, Fox KF, Ahmed A, Cousins J, Nihoyannopoulos P. Ventricular remodelling post-bariatric surgery: is the type of surgery relevant? A prospective study with 3D speckle tracking. *Eur Heart J Cardiovasc Imaging*. 2014;15:1256–1262.
  37. Karason K, Wallentin L, Larsson B, Sjöström L. Effects of obesity and weight loss on cardiac function and valvular performance. *Obes Res*. 1998;6:422–429.
  38. De Divitiis O, Fazio S, Maddalena G, Mancini M. Obesity and cardiac function. *Circulation*. 1981;64:477–482.
  39. Stelfox HT, Ahmed SB, Ribeiro RA, Gettings EM, Pomerantsev E, Schmidt U. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. *Crit Care Med*. 2006;34:1243–1246.
  40. Rowlatt UF, Rimoldi HJA, Lev M. The quantitative anatomy of the normal child's heart. *Pediatr Clin North Am*. 1963;10:499–588.
  41. Westaby S, Karp RB, Blackstone EH, Bishop SP. Adult human valve dimensions and their surgical significance. *Am J Cardiol*. 1984;53:552–556.
  42. Jander N, Gohlke-Bärwolf C, Bahlmann E, Gerds E, Boman K, Chambers JB, Egstrup K, Nienaber CA, Pedersen TR, Ray S, Rossebø AB, Willenheimer R, Kienle R-P, Wachtell K, Neumann F-J, Minners J. Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis. *Heart*. 2014;100:28–33.
  43. Tribouilloy C, Bohbot Y, Maréchaux S, Debry N, Delpierre Q, Peltier M, Diouf M, Slama M, Messika-Zeitoun D, Rusinaru D. Outcome implication of aortic valve area normalized to body size in asymptomatic aortic stenosis. *Circ Cardiovasc Imaging*. 2016;9:e005121.
  44. van Gils L, Clavel M-A, Vollema EM, Hahn RT, Spitzer E, Delgado V, Nazif T, De Jaegere PP, Geleijnse ML, Ben-Yehuda O, Bax JJ, Leon MB, Pibarot P, Van Mieghem NM. Prognostic implications of moderate aortic stenosis in patients with left ventricular systolic dysfunction. *J Am Coll Cardiol*. 2017;69:2383–2392.
  45. Rogge BP, Gerds E, Cramariuc D, Bahlmann E, Jander N, Gohlke-Bärwolf C, Pedersen TR, Lønnebakken MT. Impact of obesity and nonobesity on grading the severity of aortic valve stenosis. *Am J Cardiol*. 2014;113:1532–1535.
  46. Milano AD, De Carlo M, Mecozzi G, D'Alfonso A, Sciotti G, Nardi C, Bortolotti U. Clinical outcome in patients with 19-mm and 21-mm St. Jude aortic prostheses: comparison at long-term follow-up. *Ann Thorac Surg*. 2002;73:37–43.
  47. Blais C, Dumesnil JG, Baillet R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. *Circulation*. 2003;108:983–988.
  48. Mohty D, Dumesnil JG, Echahidi N, Mathieu P, Dagenais F, Voisine P, Pibarot P. Impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement. *J Am Coll Cardiol*. 2009;53:39–47.
  49. Coisne A, Ninni S, Edmé J-L, Modine T, Mouton S, Pilato R, Ridon H, Richardson M, Klein C, Ortmans S, Seunes C, Madika A-L, Ledieu G, Jacquelinet M, Boutie B, Altes A, Vincent F, Koussa M, Jegou B, Vincentelli A, Juthier F, Robin E, Staels B, Lancellotti P, Montaigne D. Obesity paradox in the clinical significance of effective prosthetic orifice area after aortic valve replacement. *JACC Cardiovasc Imaging*. 2019;12:208–210.
  50. Dayan V, Vignolo G, Soca G, Paganini JJ, Brusich D, Pibarot P. Predictors and outcomes of prosthesis-patient mismatch after aortic valve replacement. *JACC Cardiovasc Imaging*. 2016;9:924–933.
  51. Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai ND, Malenka DJ, Thourani VH, Rymer J, Kosinski AS. Prosthesis-patient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TAVI registry. *J Am Coll Cardiol*. 2018;72:2701–2711.
  52. Fallon JM, DeSimone JP, Brennan JM, O'Brien S, Thibault DP, DiScipio AW, Pibarot P, Jacobs JP, Malenka DJ. The incidence and consequence of prosthesis-patient mismatch after surgical aortic valve replacement. *Ann Thorac Surg*. 2018;106:14–22.

**Key Words:** body mass index • echocardiography • obesity